Literature DB >> 12070047

Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia.

Stephen F Garner1, Kate Campbell, Paul Metcalfe, Jane Keidan, Elly Huiskes, Jing-Fei Dong, José A López, Willem H Ouwehand.   

Abstract

Autoimmune thrombocytopenia is generally caused by autoantibodies against glycoprotein (GP) IIb-IIIa or GPIb-IX and occasionally against GPIa-IIa or GPV. By investigating 38 rheumatoid arthritis (RA) patients on gold therapy, 10 with profound thrombocytopenia and 28 nonthrombocytopenic controls, we showed that in all 10 patients with thrombocytopenia, the platelet autoantibodies preferentially targeted GPV but the presence of gold was not required for their reactivity. Elevated levels of platelet-associated IgG (PAIgG) were observed in 8 of the 10 patients in whom the tests were performed. In 5 patients with sufficient autologous platelets, the GPV specificity of PAIgG was confirmed. Tests with GPV transfectants revealed that the antibodies reacted with GPV independent of GPIb alpha, GPIb beta, or GPIX. Autoantibodies recognizing GPV were not seen in the 28 nonthrombocytopenic control RA patients. Thus, GPV seems to be targeted in gold-induced autoimmune thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12070047     DOI: 10.1182/blood.v100.1.344

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.

Authors:  Jessica A Reese; Xiaoning Li; Manfred Hauben; Richard H Aster; Daniel W Bougie; Brian R Curtis; James N George; Sara K Vesely
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

Review 2.  The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura.

Authors:  Masataka Kuwana; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

3.  Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.

Authors:  Richard Vollenberg; Rabie Jouni; Peter A A Norris; Monika Burg-Roderfeld; Nina Cooper; Mathias J Rummel; Gregor Bein; Irene Marini; Behnaz Bayat; Richard Burack; Alan H Lazarus; Tamam Bakchoul; Ulrich J Sachs
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

Review 4.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.